PARP Inhibition Sensitizes to Low Dose-Rate Radiation TMPRSS2-ERG Fusion Gene-Expressing and PTEN-Deficient Prostate Cancer Cells

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Chatterjee, Payel ^a,c   Choudhary, Gaurav S ^a,d   Sharma, Arishya ^a,e   Singh, Kamini ^a   Heston, Warren D ^a   Ciezki, Jay ^b   Klein, Eric A ^a   Almasan, Alexandru ^a,b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

^c KENT STATE UNIVERSITY   (United States)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

^e CLEVELAND STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; CO 338; HYBRID PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; RUCAPARIB; TMPRSS2 TRANSCRIPTION FACTOR ERG FUSION PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BRACHYTHERAPY; CANCER CELL; CELL INTERACTION; CELL SURVIVAL; CHEMORADIOTHERAPY; CLINICAL EFFECTIVENESS; CLONOGENESIS; CONTROLLED STUDY; DNA STRAND BREAKAGE; ENZYME INHIBITION; EXTERNAL BEAM RADIOTHERAPY; FUSION GENE; GENE EXPRESSION; GENE FUSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IONIZING RADIATION; PROSTATE CANCER; RADIATION DOSE; RADIATION RESPONSE; RADIOSENSITIVITY; SENESCENCE; TMPRSS2 TRANSCRIPTION FACTOR ERG GENE;

CELL AGING; CELL LINE; CELL LINE, TUMOR; CELL SURVIVAL; CHROMONES; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; INDOLES; MALE; MORPHOLINES; POLY(ADP-RIBOSE) POLYMERASES; PROSTATIC NEOPLASMS; PTEN PHOSPHOHYDROLASE; RECOMBINANT FUSION PROTEINS; SERINE ENDOPEPTIDASES; TRANS-ACTIVATORS;

EID: 84875683838     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060408     Document Type: Article

References (47)

1. Siegel R, Naishadham D, Jemal A, (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10-29.
2. Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, Poirier GG, (2010) PARP inhibition: PARP1 and beyond. Nat Rev Cancer 10: 293-301.
3. Brenner JC, Ateeq B, Li Y, Yocum AK, Cao Q, et al. (2011) Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell 19: 664-678.
4. Javle M, Curtin NJ, (2011) The role of PARP in DNA repair and its therapeutic exploitation. Br J Cancer 105: 1114-1122.
5. Sugimura K, Takebayashi S, Taguchi H, Takeda S, Okumura K, (2008) PARP-1 ensures regulation of replication fork progression by homologous recombination on damaged DNA. J Cell Biol 183: 1203-1212.
6. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, et al. (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434: 913-917.
7. Patel AG, Sarkaria JN, Kaufmann SH, (2011) Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. Proc Natl Acad Sci U S A 108: 3406-3411.
8. Albert JM, Cao C, Kim KW, Willey CD, Geng L, et al. (2007) Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clin Cancer Res 13: 3033-3042.
9. Schiewer MJ, Goodwin JF, Han S, Brenner JC, Augello MA, et al. (2012) Dual roles of PARP-1 promote cancer growth and progression. Cancer Discov.
10. Zaremba T, Thomas HD, Cole M, Coulthard SA, Plummer ER, et al. (2011) Poly(ADP-ribose) polymerase-1 (PARP-1) pharmacogenetics, activity and expression analysis in cancer patients and healthy volunteers. Biochem J 436: 671-679.
11. Lord CJ, Ashworth A, (2012) The DNA damage response and cancer therapy. Nature 481: 287-294.
12. Salmena L, Carracedo A, Pandolfi PP, (2008) Tenets of PTEN tumor suppression. Cell 133: 403-414.
13. DuPree EL, Mazumder S, Almasan A, (2004) Genotoxic stress induces expression of E2F4, leading to its association with p130 in prostate carcinoma cells. Cancer Res 64: 4390-4393.
14. Wang J, Cai Y, Yu W, Ren C, Spencer DM, et al. (2008) Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts. Cancer Res 68: 8516-8524.
15. Mazumder S, Plesca D, Kintner M, Almasan A, (2007) Interaction of a Cyclin E fragment with Ku70 regulates Bax-mediated apoptosis in hematopoietic cells. Mol Cell Biol 27: 3511-3520.
16. Kunos CA, Colussi VC, Pink J, Radivoyevitch T, Oleinick NL, (2011) Radiosensitization of human cervical cancer cells by inhibiting ribonucleotide reductase: enhanced radiation response at low-dose rates. Int J Radiat Oncol Biol Phys 80: 1198-1204.
17. Singh K, Matsuyama S, Drazba JA, Almasan A, (2012) Autophagy-dependent senescence in response to DNA damage and chronic apoptotic stress. Autophagy 8: 236- 251.
18. Ray S, Bucur O, Almasan A, (2005) Sensitization of prostate carcinoma cells to Apo2L/TRAIL by a Bcl-2 family protein inhibitor. Apoptosis 10: 1411-1418.
19. Ray S, Shyam S, Fraizer GC, Almasan A, (2007) S-phase checkpoints regulate Apo2 ligand/TRAIL and CPT-11-induced apoptosis of prostate cancer cells. Mol Cancer Ther 6: 1368-1378.
20. Crosby ME, Jacobberger J, Gupta D, Macklis RM, Almasan A, (2007) E2F4 regulates a stable G2 arrest response to genotoxic stress in prostate carcinoma. Oncogene 26: 1897-1909.
21. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, et al. (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361: 123-134.
22. Plummer R, Jones C, Middleton M, Wilson R, Evans J, et al. (2008) Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res 14: 7917-7923.
23. Curtin NJ, (2012) DNA repair dysregulation from cancer driver to therapeutic target. Nat Rev Cancer 12: 801-817.
24. Sharma A, Singh K, Almasan A, (2012) Histone H2AX phosphorylation: A marker for DNA damage. Methods Mol Biol 920: 613-626.
25. Fraser M, Zhao H, Luoto KR, Lundin C, Coackley CL, et al. (2012) PTEN deletion in prostate cancer cells does not associate with loss of RAD51 function: implications for radiotherapy and chemotherapy. Clin Cancer Res 18: 1015-1027.
26. Rubin MA, Maher CA, Chinnaiyan AM, (2011) Common gene rearrangements in prostate cancer. J Clin Oncol 29: 3659-3668.
27. Drew Y, Mulligan EA, Vong WT, Thomas HD, Kahn S, et al. (2011) Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2. J Natl Cancer Inst 103: 334-346.
28. Nag S, (2000) Brachytherapy for prostate cancer: summary of American Brachytherapy Society recommendations. Semin Urol Oncol 18: 133-136.
29. Chalmers A, Johnston P, Woodcock M, Joiner M, Marples B, (2004) PARP-1, PARP-2, and the cellular response to low doses of ionizing radiation. Int J Radiat Oncol Biol Phys 58: 410-419.
30. Ali M, Kamjoo M, Thomas HD, Kyle S, Pavlovska I, et al. (2011) The clinically active PARP inhibitor AG014699 ameliorates cardiotoxicity but doesn't enhance the efficacy of doxorubicin, despite improving tumor perfusion and radiation response in mice. Mol Cancer Ther 10: 2320-9.
31. Mukhopadhyay A, Curtin N, Plummer R, Edmondson RJ, (2011) PARP inhibitors and epithelial ovarian cancer: an approach to targeted chemotherapy and personalised medicine. BJOG 118: 429-432.
32. Liu SK, Coackley C, Krause M, Jalali F, Chan N, et al. (2008) A novel poly(ADP-ribose) polymerase inhibitor, ABT-888, radiosensitizes malignant human cell lines under hypoxia. Radiother Oncol 88: 258-268.
33. Loser DA, Shibata A, Shibata AK, Woodbine LJ, Jeggo PA, et al. (2010) Sensitization to radiation and alkylating agents by inhibitors of poly(ADP-ribose) polymerase is enhanced in cells deficient in DNA double-strand break repair. Mol Cancer Ther 9: 1775-1787.
34. Barreto-Andrade JC, Efimova EV, Mauceri HJ, Beckett MA, Sutton HG, et al. (2011) Response of human prostate cancer cells and tumors to combining PARP inhibition with ionizing radiation. Mol Cancer Ther 10: 1185-1193.
35. Hunter JE, Willmore E, Irving JA, Hostomsky Z, Veuger SJ, et al. (2011) NF-kappaB mediates radio-sensitization by the PARP-1 inhibitor, AG-014699. Oncogene.
36. Williamson CT, Muzik H, Turhan AG, Zamo A, O′Connor MJ, et al. (2010) ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors. Mol Cancer Ther 9: 347-357.
37. Hoglund A, Stromvall K, Li Y, Forshell LP, Nilsson JA, (2011) Chk2 deficiency in Myc overexpressing lymphoma cells elicits a synergistic lethal response in combination with PARP inhibition. Cell Cycle 10: 3598-3607.
38. Vilar E, Bartnik CM, Stenzel SL, Raskin L, Ahn J, et al. (2011) MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers. Cancer Res 71: 2632-2642.
39. Oplustilova L, Wolanin K, Mistrik M, Korinkova G, Simkova D, et al. (2012) Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment. Cell Cycle 11: 3837-3850.
40. Bunting SF, Callen E, Wong N, Chen HT, Polato F, et al. (2010) 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell 141: 243-254.
41. Bookstein R, Shew JY, Chen PL, Scully P, Lee WH, (1990) Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene. Science 247: 712-715.
42. Sun C, Dobi A, Mohamed A, Li H, Thangapazham RL, et al. (2008) TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. Oncogene 27: 5348-5353.
43. Carver BS, Tran J, Gopalan A, Chen Z, Shaikh S, et al. (2009) Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet 41: 619-624.
44. Swanson TA, Krueger SA, Galoforo S, Thibodeau BJ, Martinez AA, et al. (2011) TMPRSS2/ERG fusion gene expression alters chemo- and radio-responsiveness in cell culture models of androgen independent prostate cancer. Prostate: e-pub.
45. Bouchaert P, Guerif S, Debiais C, Irani J, Fromont G, (2012) DNA-PKcs Expression Predicts Response to Radiotherapy in Prostate Cancer. Int J Radiat Oncol Biol Phys. 84: 1179-85.
46. Schiewer MJ, Goodwin JF, Han S, Brenner JC, Augello MA, et al. (2012) Dual Roles of PARP-1 Promote Cancer Growth and Progression. Cancer Discov 2: 1134-1149.
47. Yin L, Rao P, Elson P, Wang J, Ittmann M, et al. (2011) Role of TMPRSS2-ERG gene fusion in negative regulation of PSMA expression. PLoS One 6: e21319.